Symphony Health Launches New Long Term Care Channel Offering

Provides industry with first integrated market alternative, presenting a complete picture of retail and non-retail channels

Print
| Source: Symphony Health Solutions

CONSHOHOCKEN, Pa., Nov. 30, 2017 (GLOBE NEWSWIRE) -- Symphony Health, a PRA Health Sciences company and a leading provider of data, cloud-based analytics and consulting solutions to life science companies and healthcare organizations, today announces the launch of their highly anticipated long term care (LTC) channel offering.  The offering provides visibility to a significant and expanding segment of retail and non-retail prescription activity.

LTC represents between 5-10% of total prescription activity across all therapeutic categories, and can be a much higher percentage within certain categories such as cardiovascular, diabetes, and depression. The LTC channel includes pharmacies that dispense medicinal preparations delivered to patients residing within an intermediate or skilled nursing facility, intermediate care facilities for the mentally disabled, hospice, assisted living facilities, group homes, and other forms of congregate living arrangements.  

Symphony Health’s LTC offering leverages the power of the IDV® (Integrated Dataverse) platform, the most comprehensive and interconnected source of healthcare data in the industry. Integration of data from multiple sources within IDV creates a consistent market view across prescriber, payer, and patient dimensions, and importantly reveals real-world behaviors which allows for better retail and non-retail tracking and measurement. The new LTC offering also provides a unique view into anonymized patient level activity associated with certain prescriptions, enabling clients to better understand the treatment journey of a LTC patient. 

“The need for LTC insights in the US is growing rapidly, making the inclusion of this channel in our overall portfolio a vital component in understanding the measurement of the full retail and non-retail prescription universe,” observed Jim Mahon, EVP, Product Management & Corporate Development. “In offering a fully integrated LTC solution, we are continuing our tradition of innovation in the market and responding to clients’ requests for IDV-derived measurement solutions.”

The LTC channel will be available in the national and sub-national PrescriberSourceTM and Non-RetailSourceTM offerings as a directly integrated data stream or warehouse feed, as well as in the PHASTTM national audit beginning with January 2018 data. It is offered as unprojected invoice transaction data or as projected retail prescription data, enhancing targeting and compensation, alignment, contracting, forecasting and market messaging activities.

For more information, visit Symphony Health or contact us at solutions@symphonyhealth.com.

About Symphony Health:
Symphony Health is a leading provider of high-value data, analytics, and technology solutions for biopharmaceutical manufacturers, healthcare providers, and payers. The company helps clients understand disease incidence, prevalence, progression, treatment and influences along the patient and prescriber journeys by connecting and integrating a broad set of primary and secondary data, and providing health research, analytics and consulting expertise. Symphony Health derived data improves health management decisions, and helps clients drive revenue growth while providing critical insights on how to effectively adapt to the changing healthcare ecosystem. For more information, visit www.symphonyhealth.com.

About PRA Health Sciences:

PRA Health Sciences (NASDAQ:PRAH) is one of the world’s leading global contract research organizations, or CROs, by revenue, providing outsourced clinical development services to the biotechnology and pharmaceutical industries. PRA’s global clinical development platform includes more than 70 offices across North America, Europe, Asia, Latin America, South Africa, Australia and the Middle East and over 14,000 employees worldwide. Since 2000, PRA has participated in approximately 3,500 clinical trials worldwide. In addition, PRA has participated in the pivotal or supportive trials that led to U.S. Food and Drug Administration or international regulatory approval of more than 70 drugs. To learn more about PRA, please visit www.prahs.com.

Media Contacts

Heather Varela                                                                                
Symphony Health
Director, Marketing Communications                                                                    
Heather.varela@symphonyhealth.com                                                  
(602) 463-7838                                                                                  

Christine Rogers
PRA Health Sciences, Inc.
Director, Public Relations
rogerschristine@prahs.com
919.786.8463